Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 468

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone: Results of a Prospective, Open-label Phase II Study

RAGHU, GANESH, CRAIG JOHNSON, W., LOCKHART, DIANE, MAGETO, YOLANDA·1999·American Journal of Respiratory and Critical Care Medicine

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive clinical syndrome of unknown etiology and fatal outcome. Currently available therapies are ineffective and associated with significant adverse effects. Pirfenidone, a new, investigational antifibrotic agent, was evaluated for its tolerability and usefulness in terminally ill patients with advanced IPF. Consecutive patients with IPF and deterioration despite conventional therapy or who were unable to tolerate or unwilling to try conventional therapy were treated with oral pirfenidone. Treatment was administered on a compassionate basis (open-label). Fifty-four patients were followed for mortality, change in lung function, and adverse effects. Their mean age was 62, mean duration of symptoms 4.6 yr, and time since lung biopsy was 3.2 yr. Conventional therapy was discontinued in 38 of 46 patients; the other eight were able to decrease their prednisone dosage and eight had no previous conventional treatment. One- and 2-yr survival was 78% (95% CI 66%, 89%) and 63% (95% CI 50%, 76%), respectively. Patients whose lung functions had deteriorated prior to enrollment appeared to stabilize after beginning treatment. Adverse effects were relatively minor. The results of this study are encouraging. Pirfenidone is a promising new treatment for IPF that is well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/ajrccm.159.4.9805017

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 468

Metadata

Authors
RAGHU, G., CRAIG JOHNSON, W., LOCKHART, D., & MAGETO, Y.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
1999-04-01
Volume
159
Issue
4
Pages
1061-1069
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2163147529
Cited by
468
References
28
FWCI
19.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone: Results of a Prospective, Open-label Phase II Study. https://app.cochat.ai/papers/10.1164/ajrccm.159.4.9805017
The paper
RAGHU, G., CRAIG JOHNSON, W., LOCKHART, D., & MAGETO, Y. (1999). Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone: Results of a Prospective, Open-label Phase II Study. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/ajrccm.159.4.9805017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.